ArticleBMC geriatrics2024
Associations between sarcopenia and circulating branched-chain amino acids: a cross-sectional study over 100,000 participants.
Article in BMC geriatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Efficacy of leucine-rich high protein supplementation on body composition and muscle function among older adults with sarcopenia: a randomized controlled trial.European journal of nutrition · 2026Trial
- Indices of obesity, malnutrition and inflammation are strong predictors of mortality in adults with type 2 diabetes: the FIELD study.Diabetologia · 2026Article
- Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.International journal of molecular sciences · 2026Review
- Article
- Pathological changes and therapeutic strategies for sarcopenia.EFORT open reviews · 2026Review
- Novel biomarkers for sarcopenia: a narrative review.Journal of orthopaedic surgery and research · 2026Review
- Article
- S100A9 as a shared biomarker and mediator of metabolic dysfunction in peripheral artery disease and sarcopenia.Frontiers in genetics · 2026Article
- Effect of fermented soy protein isolates containing collagen (Soylagen) on muscle atrophy: insight from network pharmacology analysis and experimental evidence.Frontiers in pharmacology · 2026Article
- Sarcopenia and sepsis fuel a self-perpetuating cycle of immunometabolism decline.Frontiers in immunology · 2026Review
- Gut-muscle axis in sarcopenia: from mechanisms to microbiome-based therapies.Frontiers in nutrition · 2026Review
- Potential efficacy and preliminary mechanistic insights of the Jianpi Yishen Zhuanggu Tongluo formula for rheumatoid arthritis with sarcopenia-osteopenia: an integrated pilot study.Frontiers in pharmacology · 2026Article
- The role of protein quality and amino acid composition in preventing sarcopenia and functional decline in older adults.Frontiers in nutrition · 2026Review
- The relationship between estimated glucose disposal rate and sarcopenia among middle-aged and older adults.Scientific reports · 2025Article
- Branched-chain amino acids and all-cause mortality in patients with liver cirrhosis, and the onset of diabetes in liver transplant recipients.European journal of clinical investigation · 2025Observational
- Effect of chronic kidney disease and type 2 diabetes on plasma branched-chain amino acid cross-correlation: a novel metric for evaluating homeostasis.Journal of clinical biochemistry and nutrition · 2025Article
- Diabetes and Sarcopenia: Metabolomic Signature of Pathogenic Pathways and Targeted Therapies.International journal of molecular sciences · 2025Review
- Pathophysiology of Myopenia in rheumatoid arthritis.Bone research · 2025Review
- Association between dietary animal-derived branched-chain amino acids and sarcopenia in older adults: a cross-sectional study based on Chinese community.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence suggests that alterations in BCAA metabolism may contribute to the pathogenesis of sarcopenia. However, the relationship between branched-chain amino acids (BCAAs) and sarcopenia is incompletely understood, and existing literature presents conflicting results. In this study, we conducted a community-based study involving > 100,000 United Kingdom adults to comprehensively explore the association between BCAAs and sarcopenia, and assess the potential role of muscle mass in mediating the relationship between BCAAs and muscle strength.
methodsMultivariable linear regression analysis examined the relationship between circulating BCAAs and muscle mass/strength. Logistic regression analysis assessed the impact of circulating BCAAs and quartiles of BCAAs on sarcopenia risk. Subgroup analyses explored the variations in associations across age, and gender. Mediation analysis investigated the potential mediating effect of muscle mass on the BCAA-muscle strength relationship.
resultsAmong 108,017 participants (mean age: 56.40 ± 8.09 years; 46.23% men), positive associations were observed between total BCAA, isoleucine, leucine, valine, and muscle mass (beta, 0.56-2.53; p < 0.05) and between total BCAA, leucine, valine, and muscle strength (beta, 0.91-3.44; p < 0.05). Logistic regression analysis revealed that increased circulating valine was associated with a 47% reduced sarcopenia risk (odds ratio = 0.53; 95% confidence interval = 0.3-0.94; p = 0.029). Subgroup analyses demonstrated strong associations between circulating BCAAs and muscle mass/strength in men and individuals aged ≥ 60 years. Mediation analysis suggested that muscle mass completely mediated the relationship between total BCAA, and valine levels and muscle strength, partially mediated the relationship between leucine levels and muscle strength, obscuring the true effect of isoleucine on muscle strength.
conclusionThis study suggested the potential benefits of BCAAs in preserving muscle mass/strength and highlighted muscle mass might be mediator of BCAA-muscle strength association. Our findings contribute new evidence for the clinical prevention and treatment of sarcopenia and related conditions involving muscle mass/strength loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.